Mode
Text Size
Log in / Sign up
Phase 2 N=40 Randomized Single-blind Treatment

Visual Acoustic Biofeedback for RSE Via Telepractice

Speech Sound Disorder

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Rhotic Accuracy (/r/) — 30.55; 28.60; 9.54; -.78 mean difference in percent correct

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Visual-Acoustic Biofeedback Treatment (Behavioral); No Treatment (Other)
Age
Pediatric · 9+ yrs
Sex
All
Sponsor
Montclair State University
Primary completion
Apr 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Rhotic Accuracy (/r/)
30.55; 28.60; 9.54; -.78
SECONDARY
Change in Social-emotional Well-being
2.83; 3.08

Summary

This research will meet a public health need by evaluating the efficacy of speech intervention supplemented with real-time visual-acoustic biofeedback when delivered using remote technologies.

Eligibility Criteria

Inclusion Criteria

  • Must be between 9;0 and 15;11 years of age at the time of enrollment.
  • Must speak English as the dominant language (i.e., must have begun learning English by age 2, per parent report).
  • Must speak a rhotic dialect of English.
  • Must pass a pure-tone hearing screening at 20dB hearing level.
  • Must pass a brief examination of oral structure and function.
  • Must exhibit less than 30% accuracy, based on consensus across 2 trained listeners, on a probe list eliciting rhotics in various phonetic contexts at the word level.
  • Must exhibit no more than 3 sounds other than /r/ in error on the Goldman-Fristoe Test of Articulation-3 (GFTA-3).

Exclusion Criteria

  • Must not receive a T score more than 1.3 SD below the mean on the Wechsler Abbreviated Scale of Intelligence-2 (WASI-2) Matrix Reasoning
  • Must not receive a scaled score of 7 or higher on the Recalling Sentences and Formulated Sentences subtests of the Clinical Evaluation of Language Fundamentals-5 (CELF-5).
  • Must not have an existing diagnosis of developmental disability or major neurobehavioral syndrome such as cerebral palsy, Down Syndrome, or Autism Spectrum Disorder
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04858022). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search